Literature DB >> 12019130

Combinations of lysostaphin with beta-lactams are synergistic against oxacillin-resistant Staphylococcus epidermidis.

Nandini Kiri1, Gordon Archer, Michael W Climo.   

Abstract

Oxacillin-resistant Staphylococcus aureus is rapidly killed by the endopeptidase lysostaphin, and the addition of beta-lactam antibiotics provides synergistic killing. We investigated the possibility that beta-lactams given in combination with lysostaphin would improve the activity of lysostaphin against oxacillin-resistant Staphylococcus epidermidis (ORSE), which is normally less susceptible to lysostaphin. Checkerboard synergy testing was performed for lysostaphin given in combination with oxacillin against 10 ORSE isolates for which the lysostaphin MICs were > o r= 8 microg/ml. The fractional inhibitory concentration index ranged from 0.0234 to 0.2656, indicating synergy, which was confirmed in growth curve experiments. In the rabbit model of experimental aortic valve endocarditis using an ORSE strain, the combination of lysostaphin and nafcillin was as effective as vancomycin alone and significantly better than lysostaphin or nafcillin alone. We conclude that beta-lactam antibiotics given in combination with lysostaphin are synergistic against many strains of ORSE.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12019130      PMCID: PMC127219          DOI: 10.1128/AAC.46.6.2017-2020.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  Relationship between lysostaphin endopeptidase production and cell wall composition in Staphylococcus staphylolyticus.

Authors:  J M Robinson; J K Hardman; G L Sloan
Journal:  J Bacteriol       Date:  1979-03       Impact factor: 3.490

Review 2.  Antimicrobial susceptibility of coagulase-negative staphylococci.

Authors:  G L Archer; M W Climo
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

3.  Effects of lysostaphin on Staphylococcus aureus infections of the mouse mammary gland.

Authors:  A J Bramley; R Foster
Journal:  Res Vet Sci       Date:  1990-07       Impact factor: 2.534

4.  Staphylococcal peptidoglycan interpeptide bridge biosynthesis: a novel antistaphylococcal target?

Authors:  U Kopp; M Roos; J Wecke; H Labischinski
Journal:  Microb Drug Resist       Date:  1996       Impact factor: 3.431

5.  femA, which encodes a factor essential for expression of methicillin resistance, affects glycine content of peptidoglycan in methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains.

Authors:  H Maidhof; B Reinicke; P Blümel; B Berger-Bächi; H Labischinski
Journal:  J Bacteriol       Date:  1991-06       Impact factor: 3.490

6.  Cell wall monoglycine cross-bridges and methicillin hypersusceptibility in a femAB null mutant of methicillin-resistant Staphylococcus aureus.

Authors:  A M Strandén; K Ehlert; H Labischinski; B Berger-Bächi
Journal:  J Bacteriol       Date:  1997-01       Impact factor: 3.490

7.  Lysostaphin: use of a recombinant bactericidal enzyme as a mastitis therapeutic.

Authors:  E R Oldham; M J Daley
Journal:  J Dairy Sci       Date:  1991-12       Impact factor: 4.034

8.  Systemic lysostaphin in man--apparent antimicrobial activity in a neutropenic patient.

Authors:  F R Stark; C Thornsvard; E P Flannery; M S Artenstein
Journal:  N Engl J Med       Date:  1974-08-01       Impact factor: 91.245

9.  Altered muropeptide composition in Staphylococcus aureus strains with an inactivated femA locus.

Authors:  B L de Jonge; T Sidow; Y S Chang; H Labischinski; B Berger-Bachi; D A Gage; A Tomasz
Journal:  J Bacteriol       Date:  1993-05       Impact factor: 3.490

10.  The lysostaphin endopeptidase resistance gene (epr) specifies modification of peptidoglycan cross bridges in Staphylococcus simulans and Staphylococcus aureus.

Authors:  H P DeHart; H E Heath; L S Heath; P A LeBlanc; G L Sloan
Journal:  Appl Environ Microbiol       Date:  1995-04       Impact factor: 4.792

View more
  24 in total

1.  The antimicrobial activity of marinocine, synthesized by Marinomonas mediterranea, is due to hydrogen peroxide generated by its lysine oxidase activity.

Authors:  Patricia Lucas-Elío; Daniel Gómez; Francisco Solano; Antonio Sanchez-Amat
Journal:  J Bacteriol       Date:  2006-04       Impact factor: 3.490

2.  Staphylococcus aureus biofilm as a target for single or repeated doses of oxacillin, vancomycin, linezolid and/or lysostaphin.

Authors:  E Walencka; B Sadowska; S Rózalska; W Hryniewicz; B Rózalska
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.099

3.  Bactericidal synergy of lysostaphin in combination with antimicrobial peptides.

Authors:  A P Desbois; P J Coote
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-02-11       Impact factor: 3.267

4.  Deimmunized Lysostaphin Synergizes with Small-Molecule Chemotherapies and Resensitizes Methicillin-Resistant Staphylococcus aureus to β-Lactam Antibiotics.

Authors:  Yongliang Fang; Jack R Kirsch; Liang Li; Seth A Brooks; Spencer Heim; Cynthia Tan; Susan Eszterhas; Hao D Cheng; Hongliang Zhao; Yan Q Xiong; Karl E Griswold
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

5.  Lysostaphin-resistant variants of Staphylococcus aureus demonstrate reduced fitness in vitro and in vivo.

Authors:  Caroline Kusuma; Anna Jadanova; Tanya Chanturiya; John F Kokai-Kun
Journal:  Antimicrob Agents Chemother       Date:  2006-11-13       Impact factor: 5.191

6.  Antistaphylococcal nanocomposite films based on enzyme-nanotube conjugates.

Authors:  Ravindra C Pangule; Sarah J Brooks; Cerasela Zoica Dinu; Shyam Sundhar Bale; Sharon L Salmon; Guangyu Zhu; Dennis W Metzger; Ravi S Kane; Jonathan S Dordick
Journal:  ACS Nano       Date:  2010-07-27       Impact factor: 15.881

7.  Bioluminescence and 19F magnetic resonance imaging visualize the efficacy of lysostaphin alone and in combination with oxacillin against Staphylococcus aureus in murine thigh and catheter-associated infection models.

Authors:  Tobias Hertlein; Volker Sturm; Udo Lorenz; K Sumathy; Peter Jakob; Knut Ohlsen
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

8.  Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces.

Authors:  Julie A Wu; Caroline Kusuma; James J Mond; John F Kokai-Kun
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

9.  Antibiofilm Activity and Synergistic Inhibition of Staphylococcus aureus Biofilms by Bactericidal Protein P128 in Combination with Antibiotics.

Authors:  Sandhya Nair; Srividya Desai; Nethravathi Poonacha; Aradhana Vipra; Umender Sharma
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

10.  Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol.

Authors:  Scott Walsh; Anjali Shah; James Mond
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.